- Report
- August 2024
- 175 Pages
Global
From €4754EUR$5,000USD£3,998GBP
- Report
- September 2024
- 336 Pages
Global
From €4706EUR$4,950USD£3,958GBP
- Report
- May 2024
- 139 Pages
Global
From €6179EUR$6,499USD£5,196GBP
- Report
- October 2024
- 184 Pages
Global
From €3371EUR$3,545USD£2,834GBP
€3745EUR$3,939USD£3,149GBP
- Report
- February 2025
- 273 Pages
Global
From €5182EUR$5,450USD£4,357GBP
- Report
- March 2025
- 250 Pages
Global
From €4269EUR$4,490USD£3,590GBP
- Report
- May 2024
- 132 Pages
Global
From €6179EUR$6,499USD£5,196GBP
- Report
- May 2024
- 139 Pages
Global
From €6179EUR$6,499USD£5,196GBP
- Report
- May 2024
- 138 Pages
Global
From €6179EUR$6,499USD£5,196GBP
- Report
- May 2024
- 132 Pages
Global
From €6179EUR$6,499USD£5,196GBP
- Report
- May 2024
- 136 Pages
Global
From €6179EUR$6,499USD£5,196GBP
- Report
- May 2024
- 135 Pages
Global
From €6179EUR$6,499USD£5,196GBP
- Report
- March 2025
- 196 Pages
Global
From €4706EUR$4,950USD£3,958GBP
- Clinical Trials
- August 2024
- 240 Pages
Global
From €2852EUR$3,000USD£2,399GBP
- Report
- July 2024
- 150 Pages
Global
From €3566EUR$3,750USD£2,998GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1189EUR$1,250USD£999GBP
- Report
- August 2024
- 150 Pages
Global
From €2652EUR$2,789USD£2,230GBP
- Report
- May 2024
- 100 Pages
Global
From €3756EUR$3,950USD£3,158GBP
- Report
- March 2025
Global
From €300EUR$338USD£261GBP
- Report
- August 2022
- 119 Pages
Global
From €4279EUR$4,500USD£3,598GBP

Ranibizumab is a monoclonal antibody used to treat optical disorders such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema secondary to retinal vein occlusion (RVO). It is administered as an intravitreal injection, and works by inhibiting the activity of vascular endothelial growth factor (VEGF), which is responsible for the growth of abnormal blood vessels in the eye. Ranibizumab is the first anti-VEGF drug approved by the US Food and Drug Administration (FDA) for the treatment of wet AMD, and is now widely used in the treatment of other optical disorders.
Ranibizumab is available in both branded and generic forms, and is marketed by a number of pharmaceutical companies, including Novartis, Regeneron, Genentech, and Allergan. Show Less Read more